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Abstract 89 
Background: Evidence from nationally representative studies in low- and middle-income 90 
countries (LMICs) on where patients are lost in the hypertension care continuum is sparse. This 91 
information, however, is essential for the effective design and targeting of health services 92 
interventions, and to assess progress in improving hypertension care. This study aimed to 93 
determine the cascade of hypertension care in 44 LMICs – and its variation between countries 94 
and population groups – by dividing the progression from need to successful treatment into 95 
discrete stages and measuring the losses at each stage.  96 
Methods: We pooled individual-level population-based data collected between 2005 and 2016 97 
from 44 LMICs. Hypertension was defined as systolic blood pressure (BP) ≥140 mmHg or 98 
diastolic BP ≥90 mmHg or reporting use of medication for hypertension. Among those with 99 
hypertension, we calculated the proportion who had i) ever had their BP measured, ii) been 100 
diagnosed, iii) been treated, and iv) achieved control. We disaggregated the hypertension care 101 
cascade by age, sex, education, household wealth quintile, body mass index, smoking status, 102 
country, and region. We used linear regression to predict – separately for each cascade step – a 103 
country’s performance based on gross domestic product (GDP) per capita, allowing us to identify 104 
countries whose performance fell outside of the 95% prediction interval.     105 
Findings: 1,100,507 participants were included of whom 192,441 (17.5%) had hypertension. 106 
73.6% (95% CI, 72.9 – 74.3) of those with hypertension ever had their BP measured, 39.2% 107 
(95% CI, 38.2 – 40.3) were diagnosed, 29.9% (95% CI, 28.6 - 31.3) received treatment, and 108 
10.3% (95% CI, 9.6 – 11.0) achieved control. Countries in Latin America and the Caribbean 109 
generally achieved the highest performance, while those in sub-Saharan Africa performed worst. 110 
Bangladesh, Brazil, Costa Rica, Ecuador, Kyrgyzstan, and Peru performed significantly better on 111 
all care cascade steps than predicted based on GDP per capita. Being a woman, older, more 112 
educated, wealthier, and not a current smoker were all positively associated with reaching each 113 
of the four steps of the care cascade.   114 
Interpretation: This study provides critical evidence for the design and targeting of health 115 
policies and service interventions for hypertension in LMICs by detailing at what step and for 116 
whom there are gaps in the care process in each study country. In addition, we have identified 117 
countries that perform better than expected based on their economic development in a diversity 118 
of world regions, which can guide policy decisions. Given the high disease burden caused by 119 
hypertension in LMICs, nationally representative hypertension care cascades as constructed in 120 
this study could be used as an important tracer of effective universal health coverage. 121 
Funding: Harvard McLennan Family Fund  122 
Research in context 123 
Evidence before this study: We searched MEDLINE from January 1966 until January 2019 for 124 
studies with variations of the words ‘hypertension’, ‘screened’, ‘aware’, ‘treated’, and 125 
‘controlled’ in the title or abstract. To date, the largest study of individual-level data to compare 126 
hypertension awareness, treatment, and control between low- and middle-income countries 127 
(LMICs) – and examine how these indicators vary among population groups within countries – 128 
was the Prospective Urban Rural Epidemiology (PURE) Study. However, the PURE study was 129 
based on a convenience – rather than random – sample of communities, used data from 2003 to 130 
2009, and included only 14 LMICs. 131 
Added value of this study: This is the first study based on nationally representative samples of 132 
adults in LMICs to determine where in the hypertension care process patients are lost, and how 133 
this varies between and within countries. We make four key additions to the current evidence 134 
base. First, we quantify for each of 44 LMICs the loss of individuals with hypertension at each 135 
step of the hypertension care cascade, which can guide national policy makers in whether to 136 
prioritise efforts to improve screening, diagnosis, initiation of treatment, or medication adherence 137 
and care retention. Second, we examine how the hypertension care cascade varies within LMICs 138 
between different population groups, providing important information on possible target groups 139 
for relevant interventions. Third, by benchmarking countries’ performance against their Gross 140 
Domestic Product (GDP) per capita, this analysis identifies countries that performed better than 141 
expected based on their wealth and thus likely hold valuable policy lessons for countries at a 142 
similar level of economic development. Lastly, this study provides a benchmark of health system 143 
performance for managing hypertension in LMICs against which future progress can be 144 
compared.  145 
Implications of all the available evidence: The proportion of adults with hypertension lost at 146 
each step of the hypertension care cascade varied widely between countries, with male, younger, 147 
less educated, less wealthy, and currently smoking adults generally being less likely to reach 148 
each cascade step. While the proportion who achieved control was low in all four regions 149 
examined, countries in Latin America and the Caribbean had, on average, the best care cascade 150 
indicators whereas countries in sub-Saharan Africa tended to have the lowest performance. Well-151 
designed and targeted interventions to improve hypertension care in LMICs are urgently needed. 152 
More research is required to understand why some LMICs achieve substantially better 153 
hypertension care cascade indicators than others and how the hypertension care cascade can be 154 
improved most effectively in different settings.   155 
Introduction 156 
Hypertension is a major risk factor for several common non-communicable diseases (NCDs) in 157 
low- and middle-income countries (LMICs), particularly stroke, heart disease, and chronic 158 
kidney disease.1 The prevalence of hypertension is increasing dramatically in LMICs.2 In fact, 159 
the world regions with the highest hypertension prevalence are now thought to be sub-Saharan 160 
Africa, South Asia, and Central and Eastern Europe – all regions that are largely comprised of 161 
LMICs.2  162 
 163 
Evidence regarding where in the hypertension care continuum from screening to successful 164 
treatment patients are lost to care, and how these patterns vary between and within countries, is 165 
essential to designing effective health services interventions to improve hypertension control. In 166 
addition, assessing the success of health systems in managing important – yet inexpensively 167 
treatable – NCD risk factors, like hypertension,3 would be a useful measure of health system 168 
performance that could feasibly be tracked as part of national and international targets, such as 169 
the move towards universal health coverage.4 Specifically, as LMICs undergo the 170 
epidemiological transition from acute communicable to chronic non-communicable diseases, 171 
such a health system performance measure could help track countries’ progress in shifting health 172 
services away from mainly providing episodic care for acute conditions towards furnishing long-173 
term, person-centred care for chronic conditions. 174 
 175 
Estimates of health system performance for hypertension from population-based studies in 176 
LMICs are sparse.5 This dearth of evidence – along with the projected rapid rise in the number of 177 
people with hypertension in these settings6 – was the main reason for this collaboration’s focus 178 
on LMICs rather than high-income countries. In an effort to inform the design of health services 179 
interventions and provide a cross-country comparison of health system performance for 180 
managing hypertension, this study aimed to i) determine where patients in LMICs are lost to care 181 
along the hypertension management continuum, and ii) how these patterns vary among countries 182 
and population groups within countries.  183 
 184 
Methods 185 
Data sources:  186 
We requested access to the most recent nationally representative World Health Organisation 187 
(WHO) Stepwise Approach to Surveillance (STEPS) survey conducted since 2005 for all 188 
countries that were, as per the World Bank, a LMIC at the time of the survey. This search led to 189 
access to the individual-level data of 22 surveys (Figure S1). We preferred STEPS surveys 190 
because they use the same standardised questionnaire, tend to sample a wide age range of adults, 191 
and are the official method developed by the WHO for monitoring NCD risk factors at the 192 
population level.7 For LMICs for which we were unable to acquire an eligible STEPS survey, we 193 
conducted a systematic search (Text S1), which led to the inclusion of an additional 22 survey 194 
datasets (Figure S2). Detailed information on the sampling strategy of each survey is provided in 195 
Text S2. Forty countries measured BP using a digital upper arm meter, two using a digital wrist 196 
meter, and two using a manual mercury sphygmomanometer (Table S1). Thirty-five countries 197 
measured BP three times, five two times, three two times with a third measurement if the first 198 
two differed by a pre-defined margin, and one (the Seychelles) five times.  199 
 200 
Definition of hypertension: 201 
Hypertension was defined as systolic BP ≥140mmHg or diastolic BP ≥90mmHg or reporting use 202 
of medications for hypertension. For participants with three BP measurements, we used the mean 203 
of the last two measurements (last four for the Seychelles); for participants with only two 204 
measurements, we computed the mean of both available measurements.  205 
 206 
Constructing the hypertension care cascade: 207 
We computed the percentage of all those with hypertension who had ever received a BP 208 
measurement (‘ever measured’ [step 1]), had been diagnosed with hypertension by a healthcare 209 
provider (‘diagnosed’ [step 2]), were currently taking anti-hypertensive medication (‘treated’ 210 
[step 3]), and had a normal BP (systolic BP <140mmHg and a diastolic BP <90mmHg) plus 211 
reported to have received relevant lifestyle advice and/or to be taking anti-hypertensive 212 
medication (‘controlled’ [step 4]). In supplementary analyses, we show all results when defining 213 
‘treated’ as having received relevant lifestyle advice or taking anti-hypertensive medication. 214 
More detail on the computation of the care cascade is provided in Text S3.  215 
 216 
Statistical analysis: 217 
None of the analyses presented in this manuscript were pre-specified. Countries were categorised 218 
according to the regional groupings of the WHO regional offices whereby the European and 219 
Eastern Mediterranean Region as well as the South-East Asia and Western Pacific Region were 220 
merged to avoid having only two countries with data in a region. All analyses accounted for the 221 
complex survey design using sampling weights. Our primary analyses weighted each country 222 
proportional to its population size in 2015.8 In supplementary analyses, we show all results when 223 
assigning the same weight to each country.  224 
 225 
We plotted the proportion of participants with hypertension in a country who reached each step 226 
of the care cascade against countries’ Gross Domestic Product (GDP) per capita (in constant 227 
2011 international dollars as estimated by the World Bank9) in the year of data collection for the 228 
survey to ascertain health system performance relative to a country’s wealth. In addition, we 229 
regressed – separately for each cascade step – the proportion of participants with hypertension 230 
who reached the given step on sex, ten-year age group, education, household wealth quintile, 231 
BMI group (BMI<18.5kg/m2 [underweight], 18.5≤BMI<25.0kg/m2 [normal weight], 232 
25.0≤BMI<30.0kgm2 [overweight], and BMI≥30.0kg/m2 [obese]), and a binary indicator for 233 
current tobacco smoking. Specifically, we fitted uni- and multi-variable Poisson regressions with 234 
a country-level fixed effect adjusting standard errors for clustering at the level of the primary 235 
sampling unit. In 20 countries, household wealth quintile was computed based on a principal 236 
component analysis of participants’ answers to a suite of questions on key household dwelling 237 
characteristics and household ownership of durable goods. Fourteen countries did not have these 238 
data but did have data on household income, which we used instead to create household wealth 239 
quintiles for these surveys. More detail is provided in Text S4. Household wealth, smoking, and 240 
BMI data was not available for ten, six, and five countries, respectively (Table S4). These 241 
countries were therefore removed from those regressions that included these variables as 242 
independent variables. All analyses were complete case analyses.  243 
 244 
Ethics: 245 
This study received a determination of “not human subjects research” by the institutional review 246 
board of the Harvard T.H. Chan School of Public Health on 9 May 2018. 247 
 248 
Role of the funding source:  249 
The funder had no role in study design, data collection, data analysis, data interpretation, or 250 
writing of the report. PG and LMJ had full access to all the data in the study and had final 251 
responsibility for the decision to submit for publication. 252 
 253 
Results 254 
Sample characteristics:  255 
The survey-level median response rate was 90.9% (interquartile range [IQR]: 81.5 – 95.6) 256 
(Table 1). Among those interviewed, the percentage of participants with a missing outcome (BP 257 
or response to the first cascade step) ranged from 0.0% in Belize, Romania, and the Seychelles to 258 
30.2% in Mexico, whereby the survey-level median was 2.3% (IQR: 0.6 – 8.6). 1,100,507 259 
participants with a non-missing outcome were included in the analysis. The survey-level median 260 
age among these participants was 39.5 years (IQR: 34.8 – 44.5). 192,441 (17.5%) participants 261 
had hypertension. Detailed sample characteristics are shown in Table S2-4.   262 
 263 
The hypertension care cascade by country and region: 264 
The prevalence of hypertension and undiagnosed hypertension by country and ten-year age 265 
group is shown in Table S5. Among those with hypertension, 73.6% (95% CI, 72.9 – 74.3) ever 266 
had their BP measured, 39.2% (95% CI, 38.2 – 40.3) had been diagnosed prior to the survey, 267 
29.9% (95% CI, 28.6 - 31.3) were treated, and 10.3% (95% CI, 9.6 – 11.0) had achieved control 268 
of their hypertension (Figure S3). 31.7% (95% CI, 30.6 – 32.7) of those with hypertension had 269 
received relevant lifestyle or took anti-hypertensive medication (Figure S4). The estimates for 270 
each cascade step were similar when assigning an equal weight to each country (Figure S5-6). 271 
Figure S7-10 shows the care cascade disaggregated by ten-year age group. The hypertension 272 
care cascade for each country is shown in Figure S11-12.  273 
 274 
Out of the four world regions examined, Latin America and the Caribbean had the best care 275 
cascade indicators, while sub-Saharan Africa had the worst (Figure 1 and Table S6-7). Fewer 276 
than five percent of those with hypertension had achieved control in ten of 16 countries (63%) in 277 
sub-Saharan Africa, compared to three of eight (38%) in South-East Asia and the Western 278 
Pacific, one of ten (10%) in Europe and the Eastern Mediterranean, and zero of 10 countries 279 
(0%) in Latin America and the Caribbean (Table S8). Within regions, there was substantial 280 
variation among countries with Costa Rica being the best-performing country for each cascade 281 
step in Latin America and the Caribbean. Other high-performing countries – relative to other 282 
countries in their region – were Bangladesh, Namibia, and Romania. The relative differences 283 
between regions and countries were similar when defining treatment as receiving lifestyle advice 284 
or taking anti-hypertensive medication (Figure S13), weighting countries equally (Figure S14-285 
15), and disaggregating the care cascade in each region by ten-year age group (Figure S16-17).    286 
 287 
The hypertension care cascade by Gross Domestic Product per capita: 288 
GDP per capita was positively associated with a country’s performance for each cascade step 289 
(Figure 2). Countries that performed substantially better on all cascade steps than predicted 290 
based on their GDP per capita in the year of the survey were Bangladesh, Brazil (excluding the 291 
first step as the 95% prediction interval at Brazil’s GDP per capita included perfect performance 292 
for ‘ever measured’), Costa Rica, Ecuador, Kyrgyzstan, and Peru (‘ever measured’ was not 293 
assessed in Kyrgyzstan and Peru). Countries that performed significantly worse on all cascade 294 
steps than expected based on GDP per capita were Albania (‘ever measured’ was not assessed), 295 
Indonesia (‘ever measured’ was not assessed), Tanzania, Uganda, and South Africa. These 296 
results were similar when defining treatment as receiving lifestyle advice or taking anti-297 
hypertensive medications (Figure S18), and when examining hypertension care cascade 298 
indicators by GDP per capita separately for each ten-year age group (Figure S19-22). 299 
 300 
Individual-level predictors of cascade progression: 301 
Being a woman, in an older age group, and in a higher household wealth quintile were all 302 
associated with a higher probability of reaching each cascade step in both uni- and multi-variable 303 
regressions (Table 2). In addition, except for the controlled step in the multi-variable regression, 304 
being overweight or obese was associated with a higher probability of reaching each cascade step 305 
in all regressions. Furthermore, we found that i) higher educational attainment was positively 306 
associated with reaching each cascade step once adjusted for age and sex; ii) current smokers had 307 
a lower probability of reaching each cascade step than those who did not currently smoke; and 308 
iii) being obese was associated with a higher RR of reaching each cascade step (with the 309 
exception of the controlled step in the multi-variable regression) than being overweight. The 310 
positive associations with education were strongest in low-income countries and weakest in 311 
upper middle-income countries (Table S9). By region, these positive associations with education 312 
were generally strongest in sub-Saharan Africa, and did not exist – or were significant in the 313 
negative direction in some regression models – in the Europe and Eastern Mediterranean region 314 
(Table S10). All regression results were similar when assigning the same weight to each country 315 
(Table S11-13).  316 
 317 
Stratifying the percent of participants with hypertension who reached each cascade step by sex, 318 
age group, and education (Figure 3) demonstrates that i) the proportion achieving control was 319 
less than 20% in all age and education group combinations; ii) in each educational attainment 320 
category, less than half were diagnosed in age groups below 55 years; and iii) women had a 321 
higher probability of reaching each cascade step than men in virtually all age and education 322 
group combinations. 323 
 324 
Discussion 325 
Overall, the performance of health systems in LMICs for managing hypertension was poor, with 326 
less than half of those with hypertension having been diagnosed, less than a third taking anti-327 
hypertensive medications, and only one in ten achieving control. However, there was a large 328 
degree of variation among regions and countries. Regionally, Latin America and the Caribbean 329 
performed best and sub-Saharan Africa fared worst. Relative to GDP per capita, several 330 
countries in Latin America and the Caribbean (Brazil, Costa Rica, Ecuador, and Peru) as well as 331 
Bangladesh and Kyrgyzstan performed well. Together, these findings provide an important 332 
benchmark of health system performance for managing hypertension in LMICs against which 333 
future progress can be compared.  334 
 335 
Within countries, we found that men were less likely to reach each step of the hypertension care 336 
cascade than women, which may be due to multiple factors, such as a focus of primary 337 
healthcare services on maternal and child health, gender norms concerning care-seeking, and 338 
healthcare facility opening hours. As hypertension care services are strengthened in LMICs, it 339 
will be crucial that health systems identify ways of engaging men in hypertension screening and 340 
care to avoid further widening the existing gender gap in life expectancy.10 In addition, given our 341 
finding that those who were smokers and with overweight or obesity did generally not have a 342 
higher probability of completing the hypertension cascade, it will be important for hypertension 343 
services in LMICs to more consistently reach and retain those at the highest CVD risk. Lastly, 344 
we observed that individuals with lower education and household wealth were generally more 345 
likely to be lost to care prior to completion of the cascade. This finding is especially concerning 346 
given that those of a lower socioeconomic status are likely less able to access high-quality care 347 
for, and more likely to experience catastrophic healthcare expenditures from, CVD events.11 348 
More optimistically, however, our findings also imply that well-designed investments in 349 
improving hypertension care present an opportunity to reduce health inequalities between 350 
socioeconomic groups in LMICs.  351 
 352 
Relative to their GDP per capita, countries that performed particularly well in our analysis 353 
included Costa Rica, Kyrgyzstan, and Bangladesh, implying that important lessons could be 354 
learned from the approaches adopted by these health systems. We briefly outline three possible 355 
reasons that may partially explain these countries’ comparatively strong performance. First, they 356 
have all established primary healthcare system structures at a highly local geographic level. 357 
Costa Rica’s EBAIS clinics each serve a population of 4,000 people and offer a full range of 358 
primary care and health promotion services.12 Similarly, Kyrgyzstan has established family 359 
group practices that provide comprehensive primary healthcare, with each practice serving a 360 
village of at least 2,000 inhabitants.13 Bangladesh has invested since 2009 in the establishment of 361 
approximately 14,000 community clinics, which are tasked with providing hypertension and 362 
diabetes screening.14 In addition, it has an extensive presence of informal providers, licensed and 363 
unlicensed drug stores, and non-governmental organisations throughout the country,15 which are 364 
likely also playing an important role in meeting the population’s demand for NCD care at a local 365 
level. Second, the health systems of Costa Rica and Kyrgyzstan have implemented structures that 366 
allow for effective community outreach for NCDs. Each of Costa Rica’s community clinics 367 
include at least one community health worker (CHW) who measures BP during home visits and 368 
follows up at home with patients lost from care.16,17 In addition, CHWs in Costa Rica hold health 369 
promotion sessions – including on CVD prevention – in community settings, which can help in 370 
the generation of demand for care. Kyrgyzstan has established village health committees, which 371 
consist of volunteers who were trained by primary healthcare staff to provide basic health 372 
promotion and care services, including for hypertension.13 While Bangladesh has several large-373 
scale CHW programmes,18 these mostly do not yet focus on NCDs.18 However, moving forward, 374 
the existence of these large-scale CHW programmes presents an important opportunity for the 375 
country to further improve hypertension and NCD care. Third, anti-hypertensive medications are 376 
generally both available and affordable in all three countries, which is not the norm in many 377 
LMICs.19 In Costa Rica, these medications are fully covered under the Costa Rican social 378 
security fund and widely available at primary care facilities.17 In Kyrgyzstan, a 2015 survey 379 
found that key anti-hypertensive medications were widely available and generally affordable to 380 
the local population.20 Similarly, in Bangladesh, the PURE study found that calcium-channel 381 
blockers and ß-blockers were available in 43 and 49 of 55 communities, respectively, and only 382 
7% of sampled households were unable to afford at least one type of anti-hypertensive 383 
medication.21  384 
 385 
While the hypertension care cascade is a useful measure of health system performance in 386 
LMICs, there are important contextual factors beyond the health system that likely are 387 
responsible for some of the differences in the success of hypertension management that we 388 
observed between and within countries. Perhaps most importantly, the probability of reaching 389 
each of the care cascade steps likely is affected by individuals’ socioeconomic circumstances, 390 
which in turn vary widely between and within countries. For instance, even if care is provided 391 
free of charge, time lost from income-generating activities and transport costs can still pose a 392 
substantial obstacle to accessing care for those with little income and savings.22 Likewise, 393 
individuals with a lower educational attainment may be less well-equipped to engage with 394 
relevant health promotion messages and to actively negotiate an effective treatment plan with 395 
healthcare providers. In addition to socioeconomic circumstances, epidemiological factors may 396 
affect the hypertension care cascade. For instance, adults living in populations that are exposed 397 
to a high risk of a fatal non-CVD event, such as through infectious diseases, may be less willing 398 
to invest time, effort, and money into the prevention of CVD events. Similarly, even though 399 
hypertension control can be achieved solely through medications, social and environmental 400 
factors that affect BP – such as sodium content of the food supply,23 air pollution,24 401 
conduciveness of the physical environment to physical activity,23 and social norms to diet, excess 402 
weight, and exercise – likely also have an impact on the probability that individuals achieve 403 
hypertension control, especially among adults with low medication adherence. 404 
 405 
This study has several limitations. First and foremost, while many surveys used the same WHO 406 
STEPS questionnaire to enquire about hypertension care and employed a similar approach to 407 
measuring BP, there were some differences in how questions were phrased and translated into 408 
local languages, and in how BP was measured (e.g., the exact model of BP meter). This may 409 
have affected our estimates and thus be responsible for some of the variation that we observed 410 
between countries and regions. Of note, however, is that the core elements of the questions asked 411 
about hypertension care were the same across surveys. Second, the age range sampled in each 412 
survey varied between countries. We have minimized potential bias from this data constraint by 413 
showing each figure that compares countries or regions separately for each ten-year age group 414 
(see Figure S7-10, S16-17, and S19-22). Third, while – to our knowledge – this study includes 415 
the largest set of LMICs of any study on this topic thus far, the 44 LMICs in this analysis 416 
(representing 67% of the population living in LMICs worldwide8) are not representative of all 417 
LMICs globally. Specifically, it is possible that LMICs included in this analysis had better 418 
hypertension care indicators because implementing a survey that was eligible for this study may 419 
be a sign of a country’s commitment to hypertension care. Fourth, the surveys were conducted at 420 
different time points. Each country’s performance should thus be interpreted as the performance 421 
in the given survey year rather than as the country’s current performance. To reduce bias from 422 
secular trends when comparing countries against each other, we benchmarked performance 423 
against each country’s GDP per capita in the survey year (rather than current GDP per capita). 424 
Fifth, even though the median percentage across countries of missing values for the variables 425 
needed to ascertain the hypertension care cascade was only 2.3%, some countries had a 426 
substantially higher proportion of participants with a missing outcome variable, which could 427 
have resulted in selection bias. Sixth, due to data constraints, we used the same threshold in each 428 
survey to define a BP that requires treatment. This approach, thus, ignored that guidelines in use 429 
in some countries at the time of the survey may have defined eligibility for anti-hypertensive 430 
medications differently, such as based on a global CVD risk or target-organ damage. Lastly, 431 
because we did not include a previous hypertension diagnosis in our definition of hypertension, 432 
we may have falsely excluded some participants with hypertension from our care cascade 433 
analysis. Our hypertension definition, however, is the same as was used in other studies of 434 
hypertension care,25-28 and yields conservative estimates for the care cascade under the 435 
assumption that some of those who reported a previous hypertension diagnosis, but had a normal 436 
BP and did not report to be on treatment, did, in fact, not have hypertension.  437 
 438 
This study identified important variation in the hypertension care cascade between and within 439 
countries, which can guide governments with regards to the design – such as whether to prioritise 440 
efforts to improve screening, diagnosis, treatment initiation, or medication adherence – and 441 
target groups of appropriate interventions and reforms. Given that hypertension is a major risk 442 
factor for several of the most common causes of death in LMICs,1 and that the condition can be 443 
effectively controlled at a low cost,3 the hypertension care cascade could be used as an important 444 
tracer of health system performance in LMICs. Improving hypertension care, however, will be a 445 
formidable undertaking requiring strong political will and financial commitments. 446 
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  551 
Figure legends 552 
Figure 1. The hypertension care cascade by region1,2 553 
1 Vertical error bars are 95% confidence intervals.  554 
2 Individual points depict the point estimate for each country.  555 
Abbreviations: S.E. Asia=South-East Asia; W. Pacific = Western Pacific; ALB=Albania; 556 
AZE=Azerbaijan; BGD=Bangladesh; BLZ=Belize; CRI=Costa Rica; IDN=Indonesia; 557 
KAZ=Kazakhstan; KGZ=Kyrgyz Republic; LSO=Lesotho; MEX=Mexico; MNG=Mongolia 558 
MOZ=Mozambique; NAM=Namibia; NPL=Nepal; PER=Peru; ROU=Romania; 559 
SYC=Seychelles; TLS=Timor-Leste; UGA=Uganda; ZAN=Zanzibar 560 
 561 
Figure 2. Hypertension care cascade indicators by GDP per capita1,2,3,4,5,6 562 
1 Gross Domestic Product per capita is shown in constant 2011 international dollars for the year 563 
in which the survey was carried out.  564 
2 The grey ribbon depicts the point-wise 95% prediction interval.  565 
3 The vertical bars depict 95% confidence intervals. 566 
4 The p-values for the coefficients of the linear regressions of each cascade step onto GDP per 567 
capita (with each country having the same weight) were <0.001 except for ‘Controlled’ 568 
(p=0.0014) 569 
5 Country labels are not shown for the following countries in the “controlled” plot to avoid over-570 
crowding: Benin, Burkina Faso, Comoros, Ghana, Kenya, Liberia, Mozambique, Nepal, 571 
Tanzania, Timor-Leste, Togo, and Uganda.  572 
6 The figure is shown separately for each ten-year age group in Figure S19-22. 573 
 574 
Abbreviations: ALB=Albania; AZE=Azerbaijan; BEN=Benin; BFA=Burkina Faso; 575 
BGD=Bangladesh; BLZ=Belize; BRA=Brazil; BTN=Bhutan; CHL=Chile; CHN=China; 576 
COM=Comoros; CRI=Costa Rica; ECU=Ecuador; EGY=Egypt; GDP=Gross Domestic Product; 577 
GEO=Georgia; GHA=Ghana; GRD=Grenada; GUY=Guyana; IDN=Indonesia; IND=India; 578 
KAZ=Kazakhstan; int=international; KEN=Kenya; KGZ=Kyrgyzstan; LBN=Lebanon; 579 
LBR=Liberia; LSO=Lesotho; MEX=Mexico; MNG=Mongolia; MOZ=Mozambique; 580 
NAM=Namibia; NPL=Nepal; PER=Peru; ROU=Romania; RUS=Russian Federation; 581 
SWZ=Swaziland; SYC=Seychelles; TGO=Togo; TLS=Timor-Leste; TZA=Tanzania; 582 
UGA=Uganda; UKR=Ukraine; VCT=St. Vincent & the Grenadines; ZAF=South Africa; 583 
ZAN=Zanzibar 584 
 585 
Figure 3. The percent of participants with hypertension reaching each cascade step stratified by 586 
sex, age group, and education.1,2,3 587 
1 The colour gradient and the numbers in each cell of the figure display the same point estimates. 588 
2 ‘Primary school’ refers to having received some primary schooling or having completed 589 
primary school.  590 
3 ‘High school or above’ refers to having received some secondary schooling, having completed 591 
secondary school, or having received some type of tertiary education.  592 
 593 
Table 1. Survey characteristics by region1,2 





















Latin America and the Caribbean 
Belize 2005/06 92.6 0.0 2,434 695 (28.6) 44 20-97 59.0 7,947 359 
Brazil 2013 86.0 10.6 57,466 17,517 (30.5) 41 18-101 56.5 15,430 205,962 
Chile 2009/10 85.0 8.4 4,851 1,497 (30.9) 46 15-100 59.8 18,995 17,763 
Costa Rica 2010 87.8 0.6 3,607 1,291 (35.8) 47 18-110 72.0 13,000 4,808 
Ecuador 2012 81.5 19.8 29,659 2,834 (9.6) 34 20-59 58.7 10,322 16,144 
Grenada 2011/12 67.8 2.8 1,097 460 (41.9) 44 24-64 59.9 11,249 107 
Guyana 2016 66.7 0.6 2,640 776 (29.4) 40 18-69 59.9 7,266 769 
Mexico 2009-12 90.0 30.2 20,946 5,066 (24.2) 35 15-99 56.6 15,668 125,891 
Peru  2012 94.37 5.3 29,415 7,771 (26.4) 54 40-96 52.6 10,944 31,377 
St. Vincent & 
the Grenadines 2013 67.8 0.4 3,457 1,056 (30.5) 42 18-70 55.9 10,193 109 
 
Europe and the Eastern Mediterranean 
Albania 2008 95.4 4.3 6,380 1,494 (23.4) 33 15-49 55.2 9,154 2,923 
Azerbaijan 2006 83.3 0.4 10,486 1,712 (16.3) 32 15-59 75.9 10,711 9,617 
Egypt 2015 95.0 0.5 14,790 2,476 (16.7) 33 15-59 53.0 10,096 93,778 
Georgia 2016 75.7 4.2 4,034 1,800 (44.6) 50 17-70 70.4 9,277 3,952 
Kazakhstan 2012 93.0 13.8 10,901 2,995 (27.5) 43 15-90 57.3 21,987 17,750 
Kyrgyzstan 2012 96.5 2.5 9,422 852 (9.0) 29 15-49 75.5 2,870 5,865 
Lebanon 2008/09 62.0 1.2 2,800 841 (30.0) 37 18-95 52.9 15,193 5,851 
Romania 2015/16 69.1 0.0 1,970 611 (31.0) 47 18-80 52.5 21,080 19,877 
Russia 2007/08 61.4 2.7 4,209 2,696 (64.1) 62 18-100 64.2 24,006 143,888 
Ukraine 2007 81.5 17.9 7,932 2,013 (25.4) 33 15-49 68.4 8,497 44,658 
 
South-East Asia and the Western Pacific 
Bangladesh  2011 95.0 10.4 7,593 2,052 (27.0) 48 35-96 49.5 2,571 161,201 
Bhutan 2014 96.9 0.2 2,814 1,107 (39.3) 39 18-69 61.9 7,366 787 
China 2009 88.08 9.3 9,752 2,842 (29.1) 50 15-99 52.5 8,652 1,397,029 
India 2015/16 96.0 2.0 742,838 98,451 (13.3) 30 15-54 85.6 5,924 1,309,054 
Indonesia 2014 83.0 0.7 32,492 7,882 (24.3) 35 15-110 53.2 10,003 258,162 
Mongolia 2009 95.0 0.4 5,420 1,719 (31.7) 36 15-65 40.8 7,368 2,977 
Nepal 2013 98.6 0.5 4,124 1,211 (29.4) 40 15-69 67.8 2,164 28,656 
Timor-Leste 2014 96.3 1.6 2,568 713 (27.8) 40 18-69 58.5 1,888 1,241 
 
Sub-Saharan Africa 
Benin 2008 99.0 0.3 3,799 1,218 (32.1) 42 15-65 51.5 1,841 10,576 
Burkina Faso 2013 97.8 15.1 3,993 713 (17.9) 36 25-64 53.9 1,562 18,111 
Comoros 2011 96.5 1.4 5,381 1,443 (26.8) 39 25-64 71.2 1,415 777 
Ghana 2007/08 79.4 9.6 5,030 2,677 (53.2) 60 18-110 46.7 2,760 27,583 
Kenya 2015 95.0 1.4 4,408 1,188 (27.0) 35 18-69 60.2 2,836 47,236 
Lesotho 2014 90.8 3.9 5,690 989 (17.4) 27 15-59 52.6 2,677 2,175 
Liberia 2011 87.1 1.7 2,482 719 (29.0) 36 24-64 57.9 734 4,500 
Mozambique 2005 98.3 7.0 3,073 1,102 (35.9) 38 25-64 58.4 742 28,011 
Namibia 2013 96.9 17.9 3,617 1,543 (42.7) 46 35-64 57.6 9,256 2,426 
Seychelles 2013 73.0 0.0 1,240 413 (33.3) 47 25-64 57.2 24,791 94 
South Africa  2012 39.8 3.6 6,317 2,644 (41.9) 39 15-98 64.9 12,215 55,291 
Swaziland 2014 81.8 9.9 3,183 948 (29.8) 33 15-70 65.1 7,871 1,319 
Tanzania 2012 94.7 1.2 5,636 1,737 (30.8) 40 23-65 53.8 2,228 53,880 
Togo 2010 91.0 3.7 4,190 846 (20.2) 32 15-64 52.0 1,208 7,417 
Uganda 2014 99.0 2.1 3,904 983 (25.2) 33 18-69 59.8 1,637 40,145 
Zanzibar 2011 91.0 0.7 2,467 848 (34.4) 40 24-64 61.6 1,3189 1,44110




















Abbreviations: n=number; y=years; GDP=Gross Domestic Product.  
1 Values are unweighted (i.e., do not account for the complex survey design). 
2 Except for the percent missing, all values were calculated among those with a non-missing outcome variable (i.e., no missing BP measurement or questionnaire 
answer needed to calculate the hypertension cascade).   
3 Years in which the data collection for the survey was carried out.  
4 This includes both the household and the individual response rate.    
5 This is the percent of participants for whom the blood pressure measurement was missing or a who had a missing response for the survey question needed to 
ascertain whether the participant had reached the first step of the country’s hypertension care cascade.  
6 This is the GDP per capita in constant 2011 international dollars (as estimated by the World Bank9) for the year in which data was collected for the survey. 
7 This is the response rate among women; the men’s response rate in Peru was not available.  
8 This is the response rate for the 2006 wave of the survey (the most recent wave for which a response rate was published).  
9 This is the GDP per capita in constant 2007 international dollars using data from the Office of the Chief Government Statistician of Zanzibar.29   
10 The population estimate for Zanzibar was taken from the Tanzania Population Projection Report 2013-2035.30 
11 This is the median value with each country having the same weight.  
12 This is the interquartile range. 





Table 2. Uni- and multi-variable regressions of each cascade step onto individual-level predictors1 
 Ever BP measured Diagnosed Treated Controlled 
 RR P RR P RR P RR P 
Uni-variable regressions2         
Sex         
Male 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Female 1.16 (1.14-1.18) <0.001 1.39 (1.33-1.46) <0.001 1.50 (1.41-1.58) <0.001 1.69 (1.53-1.87) <0.001 
Age group         
15-24 years 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
25-34 years 1.39 (1.33-1.46) <0.001 1.51 (1.30-1.74) <0.001 1.47 (1.22-1.77) <0.001 1.09 (0.88-1.36) 0.426 
35-44 years 1.52 (1.46-1.60) <0.001 2.18 (1.93-2.47) <0.001 2.24 (1.94-2.57) <0.001 1.27 (1.09-1.48) 0.002 
45-54 years 1.57 (1.50-1.65) <0.001 3.14 (2.79-3.52) <0.001 3.51 (3.08-4.00) <0.001 1.67 (1.44-1.92) <0.001 
55-64 years 1.57 (1.50-1.64) <0.001 3.87 (3.43-4.36) <0.001 4.78 (4.17-5.49) <0.001 2.15 (1.81-2.55) <0.001 
≥65 years 1.56 (1.48-1.64) <0.001 4.21 (3.72-4.76) <0.001 5.42 (4.72-6.22) <0.001 2.10 (1.76-2.51) <0.001 
Education         
No schooling 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Primary school3  1.08 (1.05-1.10) <0.001 0.97 (0.91-1.04) 0.454 0.97 (0.89-1.06) 0.462 1.02 (0.86-1.22) 0.807 
≥ High school4  1.13 (1.11-1.16) <0.001 0.92 (0.86-0.98) 0.014 0.88 (0.81-0.96) 0.003 1.08 (0.92-1.27) 0.322 
Household wealth quintile         
1 (poorest) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
2 1.12 (1.09-1.14) <0.001 1.12 (1.02-1.23) 0.021 1.14 (1.02-1.29) 0.024 1.19 (0.98-1.44) 0.075 
3 1.18 (1.15-1.21) <0.001 1.10 (1.00-1.20) 0.053 1.12 (1.00-1.26) 0.049 1.05 (0.87-1.27) 0.596 
4 1.26 (1.23-1.30) <0.001 1.19 (1.10-1.29) <0.001 1.25 (1.13-1.39) <0.001 1.23 (1.02-1.49) 0.026
5 (richest) 1.36 (1.32-1.40) <0.001 1.31 (1.20-1.44) <0.001 1.42 (1.27-1.58) <0.001 1.65 (1.38-1.98) <0.001 
BMI group          
Underweight 0.82 (0.78-0.85) <0.001 0.85 (0.75-0.96) 0.009 0.86 (0.72-1.02) 0.085 0.89 (0.72-1.10) 0.265 
Normal weight 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Overweight 1.16 (1.14-1.18) <0.001 1.21 (1.15-1.28) <0.001 1.22 (1.14-1.31) <0.001 1.02 (0.89-1.17) 0.730 
Obese 1.25 (1.22-1.28) <0.001 1.54 (1.43-1.66) <0.001 1.66 (1.52-1.81) <0.001 1.21 (1.05-1.40) 0.007 
Tobacco smoking         
Not currently smoking 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  




Multi-variable regression with age group, sex, and education5 
Sex         
Male 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Female 1.20 (1.18-1.23) <0.001 1.40 (1.33-1.47) <0.001 1.50 (1.42-1.59) <0.001 1.78 (1.61-1.98) <0.001 
Age group         
15-24 years 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
25-34 years 1.42 (1.36-1.49) <0.001 1.50 (1.30-1.73) <0.001 1.46 (1.22-1.76) <0.001 1.08 (0.87-1.35) 0.468 
35-44 years 1.57 (1.50-1.65) <0.001 2.12 (1.87-2.41) <0.001 2.15 (1.87-2.48) <0.001 1.23 (1.05-1.43) 0.010 
45-54 years 1.66 (1.58-1.74) <0.001 3.14 (2.79-3.54) <0.001 3.49 (3.06-3.99) <0.001 1.68 (1.45-1.95) <0.001 
55-64 years 1.66 (1.58-1.74) <0.001 3.95 (3.48-4.48) <0.001 4.86 (4.22-5.60) <0.001 2.22 (1.85-2.66) <0.001 
≥65 years 1.68 (1.59-1.77) <0.001 4.45 (3.90-5.08) <0.001 5.74 (4.96-6.64) <0.001 2.31 (1.90-2.82) <0.001 
Education         
No schooling 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Primary school3  1.14 (1.11-1.17) <0.001 1.14 (1.06-1.23) <0.001 1.18 (1.08-1.29) <0.001 1.22 (1.03-1.46) 0.024 
≥ High school4  1.26 (1.23-1.30) <0.001 1.33 (1.24-1.42) <0.001 1.39 (1.27-1.51) <0.001 1.59 (1.34-1.88) <0.001 
 
Multi-variable regressions with all predictor variables6 
Sex         
Male 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Female 1.16 (1.14-1.18) <0.001 1.26 (1.19-1.34) <0.001 1.31 (1.22-1.42) <0.001 1.54 (1.35-1.76) <0.001 
Age group         
15-24 years 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
25-34 years 1.33 (1.27-1.39) <0.001 1.29 (1.09-1.53) 0.003 1.16 (0.93-1.44) 0.187 0.95 (0.73-1.23) 0.698 
35-44 years 1.42 (1.36-1.49) <0.001 1.73 (1.49-2.01) <0.001 1.61 (1.37-1.89) <0.001 1.03 (0.85-1.23) 0.790 
45-54 years 1.50 (1.44-1.57) <0.001 2.61 (2.27-3.01) <0.001 2.67 (2.30-3.10) <0.001 1.40 (1.18-1.67) <0.001 
55-64 years 1.47 (1.40-1.54) <0.001 3.46 (2.96-4.06) <0.001 3.92 (3.31-4.64) <0.001 2.01 (1.60-2.53) <0.001 
≥65 years 1.47 (1.40-1.54) <0.001 4.02 (3.42-4.73) <0.001 4.76 (4.01-5.63) <0.001 2.11 (1.65-2.69) <0.001 
Education         
No schooling 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Primary school3  1.08 (1.05-1.11) <0.001 1.06 (0.97-1.16) 0.179 1.09 (0.98-1.21) 0.128 1.13 (0.90-1.43) 0.279 
≥ High school4  1.11 (1.09-1.14) <0.001 1.16 (1.06-1.27) 0.001 1.17 (1.05-1.31) 0.005 1.33 (1.06-1.66) 0.013 
Household wealth quintile         
1 (poorest) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
2 1.09 (1.06-1.12) <0.001 1.11 (1.00-1.23) 0.051 1.13 (1.00-1.27) 0.054 1.15 (0.91-1.44) 0.242 
3 1.14 (1.11-1.18) <0.001 1.08 (0.98-1.19) 0.119 1.12 (0.99-1.26) 0.071 1.00 (0.80-1.26) 0.993 
4 1.20 (1.16-1.24) <0.001 1.18 (1.07-1.30) 0.001 1.25 (1.11-1.41) <0.001 1.17 (0.93-1.48) 0.186 
5 (richest) 1.27 (1.23-1.31) <0.001 1.28 (1.16-1.41) <0.001 1.36 (1.21-1.53) <0.001 1.56 (1.23-1.96) <0.001 
BMI         
Underweight 0.88 (0.84-0.91) <0.001 0.84 (0.72-0.98) 0.030 0.83 (0.68-1.01) 0.057 0.87 (0.69-1.11) 0.263 
Normal weight 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Overweight 1.08 (1.06-1.10) <0.001 1.19 (1.12-1.27) <0.001 1.20 (1.11-1.30) <0.001 0.97 (0.83-1.13) 0.655
Obese 1.11 (1.09-1.13) <0.001 1.47 (1.37-1.59) <0.001 1.58 (1.45-1.72) <0.001 1.01 (0.86-1.20) 0.873 
Tobacco smoking         
Not currently smoking 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
Currently smoking 0.94 (0.92-0.97) <0.001 0.93 (0.86-1.00) 0.048 0.87 (0.79-0.96) 0.006 0.74 (0.62-0.89) 0.001 
Abbreviations: BP=blood pressure; RR=Risk Ratio; P=P-value; Ref.=reference category;   
1 Standard errors were adjusted for clustering at the level of the primary sampling unit.  
2 These regressions included only one of the variables shown in the table and a binary indicator for each country (country-level ‘fixed effects’).  
3 This refers to having received some primary schooling or having completed primary school.  
4 This refers to having received some secondary schooling, having completed secondary school, or having received some type of tertiary education.  
5 These regressions included sex, age group, education, and a binary indicator for each country (country-level ‘fixed effects’). 
6 These regressions included sex, age group, education, household wealth quintile, BMI, tobacco smoking, and a binary indicator for each country (country-level 
‘fixed effects’).  
 
 
 
